Ertapenem Versus Meropenem for the Treatment of ESBL-Producing Enterobacterales Bacteremia in Critically Ill Patients

Files

Authors

Sydney VanDorf, Beaumont Health Resident
Prakash Shah, Beaumont Health
Chad Richardson, Beaumont Health
Christine Yost, Beaumont Health

Description

The purpose of this study is to evaluate clinical outcomes for critically ill patients receiving ertapenem or meropenem for ESBL-producing Enterobacterales bacteremia.

Publication Date

12-7-2022

Keywords

extended spectrum beta-lactamase

Recommended Citation

VanDorf S, Shah P, Richardson C, Yost C. Ertapenem versus meropenem for the treatment of ESBL-producing Enterobacterales bacteremia in critically ill patients. The ASHP Midyear 2022 Clinical Meeting & Exhibition; 2022 Dec 7; Las Vegas, NV.

Comments

The ASHP Midyear 2022 Clinical Meeting & Exhibition, Las Vegas, NV, December 7, 2022.